We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study.
- Authors
Meseguer Barros, Carmen Marina; Alzueta Isturiz, Natalia; Sainz de Rozas Aparicio, Rita; Vizcaíno, Rafael Aguilella; López Esteban, Laura; Anaya Ordóñez, Sonia; Lekue Alkorta, Itxasne; Martín Suances, Salvadora; Jiménez Arce, Jorge Ignacio; Fernández Vicente, Maite; Borrego Izquierdo, Yolanda; Prieto Sánchez, Raquel; Casado Casuso, Silvia; Madridejos, Rosa; Verde, Carmen Marquina; Tomás Sanz, Rosa; Oro Fernández, María; Gallardo Borge, Sara; Lázaro López, Eva; Pina Gadea, María Belén
- Abstract
The aim of this study was to know the prevalence and severity of COVID-19 in patients treated with long-term macrolides and to describe the factors associated with worse outcomes. A cross-sectional study was conducted in Primary Care setting. Patients with macrolides dispensed continuously from 1 October 2019 to 31 March 2020, were considered. Main outcome: diagnosis of coronavirus disease-19 (COVID-19). Secondary outcomes: symptoms, severity, characteristics of patients, comorbidities, concomitant treatments. A total of 3057 patients met the inclusion criteria. Median age: 73 (64–81) years; 55% were men; 62% smokers/ex-smokers; 56% obese/overweight. Overall, 95% of patients had chronic respiratory diseases and four comorbidities as a median. Prevalence of COVID-19: 4.8%. This was in accordance with official data during the first wave of the pandemic. The most common symptoms were respiratory: shortness of breath, cough, and pneumonia. Additionally, 53% percent of patients had mild/moderate symptoms, 28% required hospital admission, and 19% died with COVID-19. The percentage of patients hospitalized and deaths were 2.6 and 5.8 times higher, respectively, in the COVID-19 group (p < 0.001). There was no evidence of a beneficial effect of long-term courses of macrolides in preventing SARS-CoV-2 infection or the progression to worse outcomes in old patients with underlying chronic respiratory diseases and a high burden of comorbidity.
- Subjects
SPAIN; SARS-CoV-2; MACROLIDE antibiotics; COUGH; COVID-19; DIAGNOSIS; RESPIRATORY diseases
- Publication
Antibiotics (2079-6382), 2021, Vol 10, Issue 9, p1039
- ISSN
2079-6382
- Publication type
Article
- DOI
10.3390/antibiotics10091039